1. Home
  2. Labeler Index
  3. Remedyrepack Inc.
  4. 70518-2109
  5. Product Images: Keppra XR

Product Images Keppra XR

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Keppra XR NDC 70518-2109 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

Keppra XR is a medication used for epilepsy treatment. This is the extended-release version of LevETIRAcetam containing 500 mg, available in a package of 30 tablets. The medicine has RX-only availability, and a lot number and expiration date are mentioned on the package. It is specifically manufactured by UCB, Inc., located in Smyrna, GA 30080. The packaging clearly instructs to keep the medicine away from children. It further contains a note indicating that the medication should be stored at 20-25°C (88-77°F), with excursions up to 15-30°C (59-86°F) allowable. The package insert should be followed for usage. RemedyRepack Inc, Indiana, PA 15701, 724.465.8762, repackaged the medicine.*

Chemical Structure - keppraxr 01

Chemical Structure - keppraxr 01

Figure 1 - keppraxr 02

Figure 1 - keppraxr 02

This appears to be a table or chart displaying the results of a medication trial. The columns show the percentage of patients with a certain effect or outcome, with different doses of Keppra and a placebo. However, without more context it is difficult to determine exactly what the numbers represent and what the purpose of the trial was.*

Figure 2 - keppraxr 03

Figure 2 - keppraxr 03

Figure 3 - keppraxr 04

Figure 3 - keppraxr 04

This text contains data related to the percentage of patients who were administered a particular treatment and the number of patients in the placebo group. The treatment mentioned is immediate-release KEPPRA with a dosage of 3000 mg/day. The percentage of patients who received the treatment is not specified clearly. The data presented in this text seems incomplete and insufficient to provide a useful description.*

Figure 4 - keppraxr 05

Figure 4 - keppraxr 05

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.